Non-invasive diagnosis is a procedure of identifying a disease without or with minimal incision of the body. These methods involve different techniques such as identifying genetic structure, biomarkers, changes in molecular biology, along with imaging technologies. Cancer is a disease related to genetic alteration of the cells and therefore causing uncontrolled growth and forming tumor like structure. Imaging is the preferred method of cancer detection but cannot have genetic access; on the other hand biopsies which have genetic access are complicated and difficult to perform repetitively during the course of cancer diagnosis and therapy. Therefore newer techniques developed in lines with non invasive diagnosis such as molecular diagnosis, serum based immunoassays and chemical tests to identify chemical components in the body especially from blood and urine. All these procedures are performed either with non-surgical or minimal surgical procedures; therefore these non-invasive cancer diagnostic techniques are becoming more and more popular among healthcare practitioners.
This report aims to provide a comprehensive presentation of the global market for Noninvasive Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Cancer Diagnostics. This report contains market size and forecasts of Noninvasive Cancer Diagnostics in global, including the following market information:
Global Noninvasive Cancer Diagnostics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Noninvasive Cancer Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Clinical Chemistry Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Noninvasive Cancer Diagnostics include Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.), Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.) and Gen-Probe Incorporated (U.S.), etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Noninvasive Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Noninvasive Cancer Diagnostics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Noninvasive Cancer Diagnostics Market Segment Percentages, by Type, 2022 (%)
Clinical Chemistry
Immunochemistry/Immunoassay
Molecular Diagnostics
Others
Global Noninvasive Cancer Diagnostics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Noninvasive Cancer Diagnostics Market Segment Percentages, by Application, 2022 (%)
Solid Tumors
Blood Cancer
Lung Cancer
Breast Cancer
Others
Global Noninvasive Cancer Diagnostics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Noninvasive Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Noninvasive Cancer Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Noninvasive Cancer Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Precision Therapeutics, Inc. (U.S.)
A&G Pharmaceutical, Inc. (U.S.)
Affymetrix Inc. (U.S.)
AVIVA Biosciences Corporation (U.S.)
BIOVIEW Inc. (U.S.)
Laboratory Corporation of America Holdings (LabCorp) (U.S.)
Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
Digene Corporation (U.S.)
Gen-Probe Incorporated (U.S.)
IVDiagnostics, Inc. (U.S.)
Outline of Major Chapters:
Chapter 1: Introduces the definition of Noninvasive Cancer Diagnostics, market overview.
Chapter 2: Global Noninvasive Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Noninvasive Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Noninvasive Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Noninvasive Cancer Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Noninvasive Cancer Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Noninvasive Cancer Diagnostics Overall Market Size
2.1 Global Noninvasive Cancer Diagnostics Market Size: 2022 VS 2029
2.2 Global Noninvasive Cancer Diagnostics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Noninvasive Cancer Diagnostics Players in Global Market
3.2 Top Global Noninvasive Cancer Diagnostics Companies Ranked by Revenue
3.3 Global Noninvasive Cancer Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Noninvasive Cancer Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Noninvasive Cancer Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Noninvasive Cancer Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Noninvasive Cancer Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Noninvasive Cancer Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Noninvasive Cancer Diagnostics Market Size Markets, 2022 & 2029
4.1.2 Clinical Chemistry
4.1.3 Immunochemistry/Immunoassay
4.1.4 Molecular Diagnostics
4.1.5 Others
4.2 By Type - Global Noninvasive Cancer Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Noninvasive Cancer Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Noninvasive Cancer Diagnostics Revenue, 2024-2029
4.2.3 By Type - Global Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Noninvasive Cancer Diagnostics Market Size, 2022 & 2029
5.1.2 Solid Tumors
5.1.3 Blood Cancer
5.1.4 Lung Cancer
5.1.5 Breast Cancer
5.1.6 Others
5.2 By Application - Global Noninvasive Cancer Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Noninvasive Cancer Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Noninvasive Cancer Diagnostics Revenue, 2024-2029
5.2.3 By Application - Global Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Noninvasive Cancer Diagnostics Market Size, 2022 & 2029
6.2 By Region - Global Noninvasive Cancer Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Noninvasive Cancer Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Noninvasive Cancer Diagnostics Revenue, 2024-2029
6.2.3 By Region - Global Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Noninvasive Cancer Diagnostics Revenue, 2018-2029
6.3.2 US Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.3.3 Canada Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.3.4 Mexico Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Noninvasive Cancer Diagnostics Revenue, 2018-2029
6.4.2 Germany Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.4.3 France Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.4.4 U.K. Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.4.5 Italy Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.4.6 Russia Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.4.7 Nordic Countries Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.4.8 Benelux Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Noninvasive Cancer Diagnostics Revenue, 2018-2029
6.5.2 China Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.5.3 Japan Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.5.4 South Korea Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.5.5 Southeast Asia Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.5.6 India Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Noninvasive Cancer Diagnostics Revenue, 2018-2029
6.6.2 Brazil Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.6.3 Argentina Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Noninvasive Cancer Diagnostics Revenue, 2018-2029
6.7.2 Turkey Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.7.3 Israel Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.7.4 Saudi Arabia Noninvasive Cancer Diagnostics Market Size, 2018-2029
6.7.5 UAE Noninvasive Cancer Diagnostics Market Size, 2018-2029
7 Noninvasive Cancer Diagnostics Companies Profiles
7.1 Precision Therapeutics, Inc. (U.S.)
7.1.1 Precision Therapeutics, Inc. (U.S.) Company Summary
7.1.2 Precision Therapeutics, Inc. (U.S.) Business Overview
7.1.3 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.1.4 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.1.5 Precision Therapeutics, Inc. (U.S.) Key News & Latest Developments
7.2 A&G Pharmaceutical, Inc. (U.S.)
7.2.1 A&G Pharmaceutical, Inc. (U.S.) Company Summary
7.2.2 A&G Pharmaceutical, Inc. (U.S.) Business Overview
7.2.3 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.2.4 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.2.5 A&G Pharmaceutical, Inc. (U.S.) Key News & Latest Developments
7.3 Affymetrix Inc. (U.S.)
7.3.1 Affymetrix Inc. (U.S.) Company Summary
7.3.2 Affymetrix Inc. (U.S.) Business Overview
7.3.3 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.3.4 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Affymetrix Inc. (U.S.) Key News & Latest Developments
7.4 AVIVA Biosciences Corporation (U.S.)
7.4.1 AVIVA Biosciences Corporation (U.S.) Company Summary
7.4.2 AVIVA Biosciences Corporation (U.S.) Business Overview
7.4.3 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.4.4 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.4.5 AVIVA Biosciences Corporation (U.S.) Key News & Latest Developments
7.5 BIOVIEW Inc. (U.S.)
7.5.1 BIOVIEW Inc. (U.S.) Company Summary
7.5.2 BIOVIEW Inc. (U.S.) Business Overview
7.5.3 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.5.4 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.5.5 BIOVIEW Inc. (U.S.) Key News & Latest Developments
7.6 Laboratory Corporation of America Holdings (LabCorp) (U.S.)
7.6.1 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Company Summary
7.6.2 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Business Overview
7.6.3 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.6.4 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.6.5 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Key News & Latest Developments
7.7 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
7.7.1 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Company Summary
7.7.2 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Business Overview
7.7.3 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.7.4 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.7.5 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Key News & Latest Developments
7.8 Digene Corporation (U.S.)
7.8.1 Digene Corporation (U.S.) Company Summary
7.8.2 Digene Corporation (U.S.) Business Overview
7.8.3 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.8.4 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Digene Corporation (U.S.) Key News & Latest Developments
7.9 Gen-Probe Incorporated (U.S.)
7.9.1 Gen-Probe Incorporated (U.S.) Company Summary
7.9.2 Gen-Probe Incorporated (U.S.) Business Overview
7.9.3 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.9.4 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.9.5 Gen-Probe Incorporated (U.S.) Key News & Latest Developments
7.10 IVDiagnostics, Inc. (U.S.)
7.10.1 IVDiagnostics, Inc. (U.S.) Company Summary
7.10.2 IVDiagnostics, Inc. (U.S.) Business Overview
7.10.3 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Major Product Offerings
7.10.4 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue in Global Market (2018-2023)
7.10.5 IVDiagnostics, Inc. (U.S.) Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Noninvasive Cancer Diagnostics Market Opportunities & Trends in Global Market
Table 2. Noninvasive Cancer Diagnostics Market Drivers in Global Market
Table 3. Noninvasive Cancer Diagnostics Market Restraints in Global Market
Table 4. Key Players of Noninvasive Cancer Diagnostics in Global Market
Table 5. Top Noninvasive Cancer Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Noninvasive Cancer Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Noninvasive Cancer Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Noninvasive Cancer Diagnostics Product Type
Table 9. List of Global Tier 1 Noninvasive Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Noninvasive Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Noninvasive Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Noninvasive Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Noninvasive Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Noninvasive Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Noninvasive Cancer Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Noninvasive Cancer Diagnostics Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 30. Precision Therapeutics, Inc. (U.S.) Company Summary
Table 31. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 32. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. Precision Therapeutics, Inc. (U.S.) Key News & Latest Developments
Table 34. A&G Pharmaceutical, Inc. (U.S.) Company Summary
Table 35. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 36. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. A&G Pharmaceutical, Inc. (U.S.) Key News & Latest Developments
Table 38. Affymetrix Inc. (U.S.) Company Summary
Table 39. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 40. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. Affymetrix Inc. (U.S.) Key News & Latest Developments
Table 42. AVIVA Biosciences Corporation (U.S.) Company Summary
Table 43. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 44. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. AVIVA Biosciences Corporation (U.S.) Key News & Latest Developments
Table 46. BIOVIEW Inc. (U.S.) Company Summary
Table 47. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 48. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. BIOVIEW Inc. (U.S.) Key News & Latest Developments
Table 50. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Company Summary
Table 51. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 52. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Key News & Latest Developments
Table 54. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Company Summary
Table 55. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 56. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Key News & Latest Developments
Table 58. Digene Corporation (U.S.) Company Summary
Table 59. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 60. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. Digene Corporation (U.S.) Key News & Latest Developments
Table 62. Gen-Probe Incorporated (U.S.) Company Summary
Table 63. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 64. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 65. Gen-Probe Incorporated (U.S.) Key News & Latest Developments
Table 66. IVDiagnostics, Inc. (U.S.) Company Summary
Table 67. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Product Offerings
Table 68. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 69. IVDiagnostics, Inc. (U.S.) Key News & Latest Developments
List of Figures
Figure 1. Noninvasive Cancer Diagnostics Segment by Type in 2022
Figure 2. Noninvasive Cancer Diagnostics Segment by Application in 2022
Figure 3. Global Noninvasive Cancer Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Noninvasive Cancer Diagnostics Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Noninvasive Cancer Diagnostics Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Noninvasive Cancer Diagnostics Revenue in 2022
Figure 8. By Type - Global Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 9. By Application - Global Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 10. By Type - Global Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 12. By Application - Global Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 14. By Region - Global Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 15. By Country - North America Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 16. US Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 20. Germany Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 21. France Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 28. China Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 32. India Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 34. Brazil Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Noninvasive Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 37. Turkey Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Noninvasive Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 41. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
